Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
Latest Information Update: 22 Jul 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ADMIT
- Sponsors AbbVie
- 20 Jul 2021 Status changed from active, no longer recruiting to completed.
- 13 May 2021 Planned End Date changed from 30 Jun 2021 to 30 Jul 2021.
- 13 May 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Jul 2021.